- Home
- NCSM vs AGEN Comparison
NCSM vs AGEN Comparison
Compare NCSM & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCSM
- AGEN
- Stock Information
- Founded
- NCSM 2006
- AGEN 1994
- Country
- NCSM United States
- AGEN United States
- Employees
- NCSM N/A
- AGEN N/A
- Industry
- NCSM Oilfield Services/Equipment
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- NCSM Energy
- AGEN Health Care
- Exchange
- NCSM Nasdaq
- AGEN Nasdaq
- Market Cap
- NCSM 76.3M
- AGEN 87.7M
- IPO Year
- NCSM 2017
- AGEN 2000
- Fundamental
- Price
- NCSM $38.11
- AGEN $4.18
- Analyst Decision
- NCSM
- AGEN Buy
- Analyst Count
- NCSM 0
- AGEN 2
- Target Price
- NCSM N/A
- AGEN $14.50
- AVG Volume (30 Days)
- NCSM 12.4K
- AGEN 500.7K
- Earning Date
- NCSM 10-29-2025
- AGEN 08-11-2025
- Dividend Yield
- NCSM N/A
- AGEN N/A
- EPS Growth
- NCSM N/A
- AGEN N/A
- EPS
- NCSM 4.71
- AGEN N/A
- Revenue
- NCSM $175,468,000.00
- AGEN $101,706,000.00
- Revenue This Year
- NCSM $9.11
- AGEN $26.25
- Revenue Next Year
- NCSM $7.13
- AGEN N/A
- P/E Ratio
- NCSM $8.09
- AGEN N/A
- Revenue Growth
- NCSM 19.31
- AGEN N/A
- 52 Week Low
- NCSM $16.81
- AGEN $1.38
- 52 Week High
- NCSM $41.75
- AGEN $7.34
- Technical
- Relative Strength Index (RSI)
- NCSM 62.18
- AGEN 36.78
- Support Level
- NCSM $37.07
- AGEN $4.31
- Resistance Level
- NCSM $41.75
- AGEN $4.70
- Average True Range (ATR)
- NCSM 2.45
- AGEN 0.27
- MACD
- NCSM 0.38
- AGEN -0.02
- Stochastic Oscillator
- NCSM 63.44
- AGEN 6.94
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).